Morgan Stanley upgraded Sonova to Overweight from Equal Weight with a CHF 307 price target. The rating change is part of the firm’s 2024 outlook for European medical technology and services. The analyst expects earnings delivery to play a more prominent role in relative winners and losers in 2024 versus a multiple dominated 2023
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SONVY:
